Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer Announced
“We are extremely excited about the updated combination study protocol and grateful for the significantly expanded support from Eli Lilly to run the trial,” said Steven Quay, M.D., Ph.D., Atossa’s President and Chief Executive Officer. “As we expected, and the preliminary EVANGELINE data has confirmed, the 80 mg dose of (Z)-endoxifen has a highly favorable safety profile and delivers the desired concentration levels to optimally target PKCβ1. We also know from both the 40 mg and 80 mg EVANGELINE cohorts that premenopausal women treated with (Z)-endoxifen experience profound clinical benefit without the need for ovarian suppression. Further validating this with a head-to-head comparison of data from the two cohorts in the combination study will be extremely valuable as we continue conversations with prospective partners and regulators.”
Share:
More News
CEO Snehal Patel commented, “We are very encouraged to see that the preliminary results from FLAMINGO-01 show immune responses in both HLA-A*02 and non-HLA-A*02 patients. We are now considering the merits of adding a randomized placebo arm for non-HLA-A*02 patients, transforming this current open label third arm into effectively a
“At Ferring, we are committed to meeting the unmet needs in bladder cancer care and equipping uro-oncologists with critical evidence they need to deliver effective, and life-changing treatment,” said Joern Jakobsen, M.D., Ph.D., Vice President and Head of Global Research and Medical for Uro-Oncology and Urology, Ferring Pharmaceuticals. “These new
“We recognise the significance of Mosaic’s platform, which has identified these two assets as anchor components of a pipeline of potential combination products,” said Dr. Harren Jhoti, co-founder, president and chief executive officer of Astex. “Both drug targets are well-characterised drivers of many cancers, and we are excited to be
“We do not view today’s unsatisfactory outcome as a failure of Globo H,” Dr. Heidi Wang, CEO of OBI Pharma added. “There may come a time, with a deeper scientific understanding of the Globo H function, it may play a meaningful role once again.”
